Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace (NPCE) has announced its 2025 financial guidance and three-year strategic objectives. The company projects 2025 revenue between $92-96 million, representing 15.5-20.5% growth from 2024's expected range of $79.4-79.9 million. The gross margin target is set at 73-75%, with total operating expenses projected at $92-95 million, including $11 million in stock-based compensation.
The company's three-year strategic plan aims to establish NeuroPace as the leader in drug-resistant epilepsy therapy, targeting a 20%+ revenue CAGR. Key objectives include expanding indications to Idiopathic Generalized and Pediatric drug-resistant epilepsy patients, advancing AI tools and remote programming capabilities, enhancing patient awareness through direct-to-consumer campaigns, and achieving cash flow breakeven.
NeuroPace (NPCE) announced preliminary unaudited Q4 2024 revenue between $21.0-21.5 million, representing 17-19% growth versus Q4 2023. Full-year 2024 revenue is expected between $79.4-79.9 million, showing 21-22% growth compared to 2023 and exceeding initial guidance of $73-77 million.
The company reported cash and short-term investments of $52.8 million as of December 31, 2024, with 30,145,039 total shares outstanding. The NAUTILUS pivotal trial, evaluating RNS System for drug-resistant idiopathic generalized epilepsy, is on track to complete one-year follow-up in March 2025.
Scott Huennekens was appointed to NeuroPace's Board of Directors effective January 6th, 2025. The company will present at the J.P. Morgan Healthcare Conference on January 15th and host an Investor Day on January 28th in New York City.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA.
In addition to the presentation, the management team will engage in investor meetings throughout the conference. Interested parties can access the presentation through a live webcast, and a replay will remain available for two weeks following the event on the Events section of NeuroPace's Investor website.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced an upcoming Investor Day scheduled for January 28, 2025, in New York City. The event will run from 9:00 a.m. to 12:00 p.m. ET.
The presentation will showcase the company's RNS technology and future strategic plans. Management will discuss recent results and outline market, product, and clinical development strategies for the RNS System. The event will feature presentations from clinical key opinion leaders and include personal testimony from an RNS patient about their experience with the system.
NeuroPace (NASDAQ: NPCE) announced its participation in the 2024 American Epilepsy Society Annual Meeting (AES 2024) at the Los Angeles Convention Center from December 6-10, 2024. The company's RNS System will be featured in over 70 scientific presentations and posters.
At booth #2119, NeuroPace will showcase their responsive neuromodulation technology, highlighting 82% seizure reduction at three years and improved quality of life without chronic side effects common in other neuromodulation therapies. The company is hosting demonstrations, panels, and networking events, including a Fellows Networking Reception and a Product Theater presentation on 'New Frontiers in Responsive Neuromodulation.'
NeuroPace announced completion of enrollment and implant procedures in its feasibility IDE study of the RNS System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood-onset epilepsy. The study, funded by a $9.3 million NIH grant, enrolled 20 patients aged 12 and older across six sites to evaluate the safety and effectiveness of brain-responsive stimulation for LGS treatment.
The study includes a one-year open label period followed by an 18-month long-term follow-up. LGS affects patients severely, with 85% continuing to have seizures into adulthood, 98% suffering from intellectual disability, and affected individuals being 12 times more likely to die prematurely than their peers.
NeuroPace reported a 28% year-over-year revenue increase to $21.1 million in Q3 2024, driven by higher RNS System sales. The company raised its full-year 2024 revenue guidance to $78-80 million. Gross margin was strong at 73.2%. Cash burn decreased to $1.8 million, with an increase in cash and short-term investments to $56.8 million. Operating expenses rose to $19.7 million, primarily due to increased R&D and SG&A costs. Net loss narrowed to $5.5 million from $7.3 million in Q3 2023. Management highlighted positive three-year data from a Post-Approval Study and announced an investor day in Q1 2025.
NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. The study, involving over 300 patients from more than 30 Level 4 Comprehensive Epilepsy Centers in the US, is the largest prospective trial in neuromodulation for drug-resistant focal epilepsy. The RNS System is the only neuromodulation device that provides stimulation and monitors patient response over time. The study will continue to a five-year follow-up endpoint as part of the system's initial FDA approval.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, has announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors can access a live and archived webcast of the event at the provided link. Those interested in participating via telephone can dial +1-877-407-3982 and reference Conference ID 13749123. The webcast will be archived on the company's investor relations website for at least 90 days after the event.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has appointed Amy Treadwell as its new Vice President of Human Resources. CEO Joel Becker emphasized the importance of this appointment in supporting the company's growth and capitalizing on commercial, operating, and technological opportunities. Ms. Treadwell brings significant experience from healthcare and technology roles, having previously served as VP of People at CyCognito and held HR leadership positions at Carbon Health, Fitbit, and eBay.
This appointment, along with recent additions of Brett Wingeier as VP of Research and Development and Katie Keller as VP of Marketing, aims to strengthen NeuroPace's management team and enhance its strategy to increase access, adoption, and utilization of RNS therapy. Ms. Treadwell holds a Juris Doctor degree from Santa Clara University School of Law and a Bachelor's degree in International Relations from the University of Southern California.